When FDA approval does come, the indication will be for treatment only in HIV patients. Roche is working with the NIH 's AIDS Clinical Trials Group to design prevention trials, but these will be larger and longer studies. In order to be a viable, cost-effective option for CMV prevention, valganciclovir will need to be more effective and priced lower than the hugely expensive Cytovene capsules. Reproduced with permission. Inc. All rights reserved.
Noncommercial reproduction is encouraged.
Subscription lists are kept confidential. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only.